A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood. People with sickle cell disease (SCD) say a ...

LMP Capital and Income Fund offers a 9.7% yield, focusing on income generation through a diversified asset mix, but has underperformed recently. SCD trades at an 8.68% discount to NAV, yet remains ...

SCD seeks total returns with a primary focus on income, investing globally in companies with strong fundamentals and clear market advantages. The fund uses leverage to enhance returns, with interest ...

Adults with type 1 diabetes (T1D) and type 2 diabetes (T2D) face substantially higher rates of sudden cardiac death (SCD) across all age groups, especially younger adults, according to findings from a ...

Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...

An ex vivo gene-edited cell therapy for sickle cell disease (SCD) being developed by Sangamo Therapeutics and Sanofi has generated positive early Phase I/II results in three patients—data that ...

SCD is often promoted for people with inflammatory bowel diseases (IBD), but very few studies support its effectiveness. Over the last decade, the incidence of IBD has increased worldwide. Symptoms ...